What is HC Wainwright’s Forecast for CRVS Q2 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Friday, May 15th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.17) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.66) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.63) EPS and FY2028 earnings at ($0.25) EPS.

Other equities analysts also recently issued reports about the company. The Goldman Sachs Group initiated coverage on Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $40.00 target price for the company. Jefferies Financial Group increased their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Oppenheimer reissued an “outperform” rating and set a $33.00 target price (up from $32.00) on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Finally, Barclays increased their target price on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.33.

Corvus Pharmaceuticals Stock Down 0.8%

CRVS opened at $12.21 on Tuesday. The business has a 50 day moving average price of $15.07 and a two-hundred day moving average price of $13.18. The company has a market cap of $1.03 billion, a PE ratio of -23.48 and a beta of 0.94. Corvus Pharmaceuticals has a 52 week low of $3.38 and a 52 week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01).

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its stake in shares of Corvus Pharmaceuticals by 481.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock worth $1,489,000 after buying an additional 84,282 shares in the last quarter. Quantinno Capital Management LP purchased a new position in Corvus Pharmaceuticals in the 1st quarter valued at approximately $336,000. Commodore Capital LP purchased a new position in Corvus Pharmaceuticals in the 1st quarter valued at approximately $33,045,000. Spruce Street Capital LP purchased a new position in Corvus Pharmaceuticals in the 1st quarter valued at approximately $3,388,000. Finally, Renaissance Technologies LLC purchased a new position in Corvus Pharmaceuticals in the 1st quarter valued at approximately $1,190,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

More Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Neutral Sentiment: HC Wainwright maintained a Buy rating on Corvus Pharmaceuticals and reiterated a $27 price target, signaling continued long-term confidence despite lower earnings assumptions.
• Positive Sentiment: The firm’s price target remains well above the current trading range, which may support investor expectations for upside if the company executes on its pipeline and clinical milestones.
• Negative Sentiment: HC Wainwright lowered EPS estimates for FY2026, FY2027, FY2028, and several quarterly periods, reflecting a more conservative outlook on Corvus Pharmaceuticals’ near- and medium-term earnings trajectory. Article Title

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.